Search





Search





Markets
/
Stocks
/
bolt
/

Bolt Biotherapeutics Inc

BOLT

Add to Watchlist

3.990USD

+0.100+2.57%

Close 07-31 16:00（ET）Quotes delayed by 15 min

7.66MMarket Cap

LossP/E TTM

Bolt Biotherapeutics Inc

3.990

+0.100+2.57%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

+2.57%

5 Days

+4.18%

1 Month

+3.64%

6 Months

-32.37%

Year to Date

-27.03%

1 Year

-29.38%

Key Figures

3.970Open

4.140High

19.50KVolume

LossP/E TTM

LossP/E Dynamic

--Dividend TTM

1.02%Turnover Ratio

3.890Prev. Close

3.940Low

62.95KTurnover

LossP/E Static

0.29P/B

0.00%Div Yield TTM

-44.19%ROA

7.35052wk High

2.90Volume Ratio

-63.12MNet Profit

1.92MShares

-16.4006EPS TTM

1.12Beta

-88.79%ROE

3.91052wk Low

5.14%Amplitude

100.00%Gross Margin

7.66MMarket Cap

-0.92Reward/Risk

4.29%Risk Rate

TradingKey Stock Score of Bolt Biotherapeutics Inc

Currency: USD Updated: 2026-07-31

Key Insights

Bolt Biotherapeutics Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 163 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 29.00.In the medium term, the stock price is expected to trend down.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bolt Biotherapeutics Inc's Score

Industry at a Glance

Industry Ranking

163 / 385

Overall Ranking

249 / 4281

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Bolt Biotherapeutics Inc Highlights

StrengthsRisks

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Growing

The company is in a growing phase, with the latest annual income totaling USD 7.70M.

Fairly Valued

The company’s latest PE is -0.24, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 516.47K shares, decreasing 49.40% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.26.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

29.000

Target Price

+653.25%

Upside Space

Bolt Biotherapeutics Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 4 analysts

Buy

Current Rating

29.000

Target Price

+653.25%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

496

Total

Median

Average

Company name

Ratings

Analysts

Bolt Biotherapeutics Inc

BOLT

Beigene Ltd

ONC

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Ionis Pharmaceuticals Inc

IONS

Insmed Inc

INSM

...

Indicators

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.010

Neutral

RSI(14)

47.028

Neutral

STOCH(KDJ)(9,3,3)

27.263

Neutral

ATR(14)

0.273

Low Volatility

CCI(14)

-25.039

Neutral

Williams %R

70.833

Sell

TRIX(12,20)

-0.285

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

3.945

Buy

MA10

3.995

Sell

MA20

4.023

Sell

MA50

4.338

Sell

MA100

4.492

Sell

MA200

4.947

Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Bolt Biotherapeutics Inc Info

Ticker SymbolBOLT

CompanyBolt Biotherapeutics Inc

CEOQuinn (William P)

Websitehttps://boltbio.com/

Shareholders

Shareholders

Proportion

Sofinnova Investments, Inc

7.17%

Vivo Capital, LLC

3.77%

Renaissance Technologies LLC

2.86%

Pivotal Bioventure Partners Investment Advisor LLC

2.74%

Quinn (William P)

2.20%

Other

81.27%

Popular Instruments

FAQs

What is the current price of Bolt Biotherapeutics Inc (BOLT)?



The current price of Bolt Biotherapeutics Inc (BOLT) is 3.99.

What is the symbol of Bolt Biotherapeutics Inc?



The ticker symbol of Bolt Biotherapeutics Inc is BOLT.

What is the 52-week high of Bolt Biotherapeutics Inc?



The 52-week high of Bolt Biotherapeutics Inc is 7.35.

What is the 52-week low of Bolt Biotherapeutics Inc?



The 52-week low of Bolt Biotherapeutics Inc is 3.91.

What is the market capitalization of Bolt Biotherapeutics Inc?



The market capitalization of Bolt Biotherapeutics Inc is 7.66M.

Is Bolt Biotherapeutics Inc (BOLT) currently rated as Buy, Hold, or Sell?



According to analysts, Bolt Biotherapeutics Inc (BOLT) has an overall rating of Buy, with a price target of 29.00.

What is the Earnings Per Share (EPS TTM) of Bolt Biotherapeutics Inc (BOLT)?



The Earnings Per Share (EPS TTM) of Bolt Biotherapeutics Inc (BOLT) is -17.85.